*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>A fixed-dose combination antiretroviral therapy integrating <strong>Dolutegravir</strong>, <strong>Emtricitabine</strong>, and <strong>Tenofovir Alafenamide</strong>. This pharmaceutical blend utilizes advanced crystallization processes to ensure high purity. Molecular formula: C20H19N7O5S2; CAS: 850674-66-3 (Dolutegravir).</p>
<h3>Application</h3>
<ul>
<li>HIV-1 treatment in adults and pediatric patients.</li>
<li>Pre-exposure prophylaxis (PrEP) for high-risk populations.</li>
<li>Manufacturing of oral tablets for global distribution networks.</li>
</ul>
<h3>Precautions</h3>
<p>Contraindicated with specific interacting drugs like rifampicin. Storage requires controlled room temperature (20°C–25°C) away from moisture. Clinical use mandates monitoring for renal function and bone density changes.</p>